| 高聆,刘春雨,孔祥辉,赵家军,冯建华.中药五岳抗甲丸对格利夫氏病患者血清粘附分子及甲状腺功能的影响[J].,2002,(10):754-756 |
| 中药五岳抗甲丸对格利夫氏病患者血清粘附分子及甲状腺功能的影响 |
| Effect of Wuyue Kangjia Pill on Serum Adhesive Molecule and Thyroid Function in Patients of Graves′ Disease |
| |
| DOI： |
| 中文关键词: 格利夫氏病 粘附分子 中药 |
| 英文关键词:Graves′disease adhesive factor Chinese herbal medicine |
| 基金项目:本课题受山东省优秀中青年科学家科研奖励基金资助 (No.963842 2 2 ) |
|
| Hits: 1490 |
| Download times: 1554 |
| 中文摘要: |
| 目的 :研究中西医结合治疗Graves′(格利夫氏 )病患者血清中粘附分子变化。方法 :16 8例初患格利夫氏病患者分为两组 :单纯用他巴唑或丙基硫氧嘧啶治疗组 (A组 ) ,他巴唑或丙基硫氧嘧啶合用五岳抗甲丸治疗组 (B组 ) ;另设正常对照组 (C组 )。采用酶联免疫方法 ,观察格利夫氏病患者治疗前后血清中可溶性细胞间粘附分子 (sICAM 1)和可溶性血管内皮粘附分子 (sVCAM 1)含量的变化 ;化学发光法测定甲状腺功能 (FT3、FT4、TGAb、TMAb)。结果 :A组sICAM 1治疗前、后为 (989 7± 10 5 6 ) μg/L、(75 8 8±175 8) μg/L(P >0 0 5 ) ;sVCAM 1治疗前、后为 (15 80 6± 6 19 5 ) μg/L、(1332 0± 5 32 9) μg/L(P >0 0 5 ) ;B组治疗前、后sICAM 1为 (110 0 1± 99 7) μg/L、(4 89 5± 189 9) μg/L(P <0 0 1) ,sVCAM 1为 (170 5 5±4 34 7) μg/L、(898 3± 35 8 6 ) μg/L (P <0 0 5 )。C组sICAM 1、sVCAM 1分别为 (342 5± 2 5 0 2 ) μg/L、(6 6 1 2± 32 0 8) μg/L。A、B两组治疗前sICAM 1、sVCAM 1与C组的sICAM 1、sVCAM 1分别比较 ,均显著增加 (P <0 0 1,P <0 0 5 ) ;与A组治疗后比较 ,B组治疗后血清中sICAM 1、sVCAM 1含量明显下降 (P<0 0 5 )。通过治疗 ,两组患者临床症状及甲状腺功能 |
| 英文摘要: |
| Objective: To study the effect of integrative traditional Chinese and western medical (TCMWM) treatment on serum adhesive molecule in patients with Graves′disease (GD). Methods: One hundred and sixty eight patients with GD were divided into two groups, Group A treated with methimazole (MT) or propylthiouracil (PTU) alone and Group B treated with MT or PTU combined with Wuyue Kangjia Pill (WKP). Besides, a normal group (Group C) was set up for control. The serum soluble intercellular adhesion molecule 1 (sICAM 1) and soluble vascular cell adhesion molecule (sVCAM 1) in patients before and after treatment were determined using ELISA and parameters of thyroid function as FT3, FT4, TGAb, TMAb, were detected by chemical luminescent method. Results: Before treatment, sICAM 1 in Group A, B and C was 989 7±105 6 μg/L,1100 1±99 7 μg/L and 342 5±250 2 μg/L respectively, and sVCAM 1 in the three groups was 1580 6±619 5 μg/L, 1705 5±434 7 μg/L and 661 2±320 8 μg/L, respectively. After treatment, sICAM 1 lowered to 758 8±175 8 μg/L in Group A and to 489 5±189 9 μg/L in Group B, sVCAM 1 lowered to 1332 0±532 9 μg/L in Group A and to 898 3±358 6 μg/L in Group B. As compared with the normal control, the two parameters in groups of patients before treatment were higher significantly (P<0 01 or P<0 05), as compared with before treatment, they were all lowered after treatment significantly (P<0 01 or P<0 05); and comparison between the two treated groups after treatment, the lowering was more significant in Group B (P<0 05). The thyroid function was improved in both Group A and B. Conclusion: The TCM WM therapy could reduce the serum content of sICAM 1 and sVCAM 1 in GD patients. |
| View Full Text View/Add Comment Download reader |
|
|
|
